Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.55 |
| ▸ | BRD4 | O60885 | 6/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | IL1B | P01584 | 1/20 | 0.54 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772826 | 1.00 | CRBN (0.55) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL20913681 | 1.00 | CRBN (0.55) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL24778362 | 0.98 | CRBN (0.57) | CRBNBRD4TNFIL1BIKZF1 | |
| Hydrochloric Acid SCHEMBL23037363 | 0.97 | CRBN (0.56) | CRBNBRD4TNFIL1BIKZF1 | |
| Hydrochloric Acid SCHEMBL31065058 | 0.97 | CRBN (0.56) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL19438857 | 0.93 | CRBN (0.55) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL19438825 | 0.93 | CRBN (0.55) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL20913661 | 0.93 | CRBN (0.55) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL30577345 | 0.93 | CRBN (0.55) | CRBNBRD4TNFIL1BIKZF1 | |
| Trifluoroacetic Acid SCHEMBL28907388 | 0.93 | CRBN (0.53) | CRBNBRD4TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035780-A1 | AKR1C3 TARGETED HETEROBIFUNCTIONAL SMALL MOLECULE PROTEOLYSIS TARGETING CHIMERAS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| US-20200048276-A9 | MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048276-A9 | MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180291035-A1 | MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-10-11 | — | — | US | disclosed |
| US-10017520-B2 | Myc modulators and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017520-B2 | Myc modulators and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-07-10 | — | — | US | disclosed |
| EP-3230279-A1 | FUSED 1,3-AZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Massachusetts Institute of Technology (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20160168165-A1 | MYC MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-16 | — | — | US | disclosed |
| US-20160168165-A1 | MYC MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-16 | — | — | US | disclosed |
| WO-2016094688-A1 | FUSED 1,3-AZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168165-A1 | MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | CRBN 263/4885BRD4 633/4885TNF 3881/4885 |
| US-20200048276-A9 | MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | CRBN 263/4885BRD4 633/4885TNF 3881/4885 |
| US-20180291035-A1 | MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | CRBN 263/4885BRD4 633/4885TNF 3881/4885 |
| US-10017520-B2 | Myc modulators and uses thereof | MYC, MYCBP, MYCBP2 | CRBN 263/4885BRD4 633/4885TNF 3881/4885 |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | CRBN 393/4885BRD4 75/4885TNF 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.